Skip to main content
Top
Published in: PharmacoEconomics 3/2014

01-03-2014 | Original Research Article

Does Economic Incentive Matter for Rational Use of Medicine? China’s Experience from the Essential Medicines Program

Authors: Mingsheng Chen, Lijie Wang, Wen Chen, Luying Zhang, Hongli Jiang, Wenhui Mao

Published in: PharmacoEconomics | Issue 3/2014

Login to get access

Abstract

Background

Before the new round of healthcare reform in China, primary healthcare providers could obtain a fixed 15 % or greater mark-up of profits by prescribing and selling medicines. There were concerns that this perverse incentive was a key cause of irrational medicine use. China’s new Essential Medicines Program (EMP) was launched in 2009 as part of the national health sector reform initiatives. One of its core policies was to eliminate primary care providers’ economic incentives to overprescribe or prescribe unnecessarily expensive drugs, which were regarded as consequences of China’s traditional financing system for health institutions.

Objectives

The objective of the study was to measure changes in prescribing patterns in primary healthcare facilities after the removal of the economic incentives for physicians to overprescribe as a result of the implementation of the EMP.

Methods

A comparison design was applied to 8,258 prescriptions in 2007 and 8,278 prescriptions in 2010, from 83 primary healthcare facilities nationwide. Indicators were adopted to evaluate medicine utilization, which included overall number of medicines, average number of Western and traditional Chinese medicines, pharmaceutical expenditure per outpatient prescription, and proportion of prescriptions that contained two or more antibiotics. We further assessed the use of medicines (antibiotics, infusion, hormones, and intravenous injection) per disease-specific prescription for hypertension, diabetes, coronary artery heart disease, bronchitis, upper respiratory tract infection, and gastritis. A difference-in-difference analysis was employed to evaluate the net policy effect.

Results

Overall changes in indicators were not found to be statistically significant between the 2 years. The results varied for different diseases. The number of Western drugs per outpatient prescription decreased while that of traditional Chinese medicines increased. Overuse of antibiotics remained an extensive problem in the treatment of many diseases, though there was some significant improvement in certain diseases, like diabetes in rural areas. Medicine expenditure per prescription also decreased.

Conclusions

It seems that the removal of a perverse economic incentive alone would not lead to improvement of healthcare providers’ prescribing patterns. The rationality of the Essential Medicines List and the lack of payers’ and providers’ meaningful involvement in the development of the policy possibly contribute to the lack of significant changes in prescribing behaviors. It is suggested that China should adopt more comprehensive policies for healthcare facilities, physicians, patients, and payers, rather than just relying on economic incentives to improve rational use of medicines.
Literature
1.
go back to reference Jassim Al Khaja KA, Sequeira RP, Mathur VS. Patterns of utilization of antihypertensive drug combinations in Bahrain: do they conform with international guidelines? Int J Clin Pharmacol Ther. 2000;38(12):568–80. Jassim Al Khaja KA, Sequeira RP, Mathur VS. Patterns of utilization of antihypertensive drug combinations in Bahrain: do they conform with international guidelines? Int J Clin Pharmacol Ther. 2000;38(12):568–80.
2.
go back to reference World Health Organization. Medicines use in primary care in developing and transitional countries: fact book summarizing results from studies reported between 1990 and 2006. Geneva: WHO; 2009. World Health Organization. Medicines use in primary care in developing and transitional countries: fact book summarizing results from studies reported between 1990 and 2006. Geneva: WHO; 2009.
3.
go back to reference Shivhare SC, Kunjwani HK, Manikrao AM, et al. Drugs hazards and rational use of drugs: a review. J Chem Pharm Res. 2010;2(1):106–12. Shivhare SC, Kunjwani HK, Manikrao AM, et al. Drugs hazards and rational use of drugs: a review. J Chem Pharm Res. 2010;2(1):106–12.
4.
go back to reference International Prescrire. A review of new drugs and indications in 2002: Financial speculation or better patient care? Prescrire Int. 2003;12:74–7. International Prescrire. A review of new drugs and indications in 2002: Financial speculation or better patient care? Prescrire Int. 2003;12:74–7.
5.
go back to reference Sara B, Jonathan DQ, Germán V. Public-private roles in the pharmaceutical sector: Implications for equitable access and rational drug use. Geneva: WHO; 1997. Sara B, Jonathan DQ, Germán V. Public-private roles in the pharmaceutical sector: Implications for equitable access and rational drug use. Geneva: WHO; 1997.
6.
go back to reference World Health Organization. Promoting rational use of medicines: core components. In: WHO policy perspectives on medicines. Report no. 5. Geneva: WHO; 2002. World Health Organization. Promoting rational use of medicines: core components. In: WHO policy perspectives on medicines. Report no. 5. Geneva: WHO; 2002.
7.
go back to reference Hsiao WC. The political economy of Chinese health system reform. Health Econ Policy Law. 2007;2(Pt 3):241–9.PubMedCrossRef Hsiao WC. The political economy of Chinese health system reform. Health Econ Policy Law. 2007;2(Pt 3):241–9.PubMedCrossRef
8.
go back to reference China National Health Economics Institute. China national health accounts report 2009. Beijing: Ministry of Health; 2009. China National Health Economics Institute. China national health accounts report 2009. Beijing: Ministry of Health; 2009.
9.
go back to reference Hu S, Chen W, Cheng X, et al. Pharmaceutical cost-containment policy: experiences in Shanghai, China. Health Policy Plan. 2001;16(Suppl. 2):4–9.PubMedCrossRef Hu S, Chen W, Cheng X, et al. Pharmaceutical cost-containment policy: experiences in Shanghai, China. Health Policy Plan. 2001;16(Suppl. 2):4–9.PubMedCrossRef
10.
go back to reference Chen Y, Schweitzer SO. Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific Region. Value in Health. 2008;11(Suppl. 1):124–9.CrossRef Chen Y, Schweitzer SO. Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific Region. Value in Health. 2008;11(Suppl. 1):124–9.CrossRef
11.
go back to reference Yang L. The essential medicine system in China: strategies and challenges (abstract). Value Health. 2010;533. Yang L. The essential medicine system in China: strategies and challenges (abstract). Value Health. 2010;533.
12.
13.
go back to reference Jiang Qian, Nancy Yu B, Ying G, et al. Outpatient prescription practices in rural township health centers in Sichuan province, China. BMC Health Serv Res. 2012;12(1):324.PubMedCentralPubMedCrossRef Jiang Qian, Nancy Yu B, Ying G, et al. Outpatient prescription practices in rural township health centers in Sichuan province, China. BMC Health Serv Res. 2012;12(1):324.PubMedCentralPubMedCrossRef
14.
go back to reference Liang Xiaoyun, Jin Chenggang, Wang Li, et al. Unnecessary use of antibiotics for inpatient children with pneumonia in two counties of rural China. Int J Clin Pharm. 2011;33(5):750–4.PubMedCrossRef Liang Xiaoyun, Jin Chenggang, Wang Li, et al. Unnecessary use of antibiotics for inpatient children with pneumonia in two counties of rural China. Int J Clin Pharm. 2011;33(5):750–4.PubMedCrossRef
15.
go back to reference Eggleston K, Ling L, Qingyue M, et al. Health service delivery in China: a literature review. Health Econ. 2008;17(2):149–65.PubMedCrossRef Eggleston K, Ling L, Qingyue M, et al. Health service delivery in China: a literature review. Health Econ. 2008;17(2):149–65.PubMedCrossRef
16.
go back to reference Yu X, Li C, Shi Y, et al. Pharmaceutical supply chain in China: current issues and implications for health system reform. Health Policy. 2010;97(1):8–15.PubMedCrossRef Yu X, Li C, Shi Y, et al. Pharmaceutical supply chain in China: current issues and implications for health system reform. Health Policy. 2010;97(1):8–15.PubMedCrossRef
17.
go back to reference Chen W, Tang SL, Sun J, et al. Availability and use of essential medicines in China: manufacturing, supply, and prescribing in Shandong and Gansu provinces. BMC Health Serv Res. 2010;10:211–8.PubMedCentralPubMedCrossRef Chen W, Tang SL, Sun J, et al. Availability and use of essential medicines in China: manufacturing, supply, and prescribing in Shandong and Gansu provinces. BMC Health Serv Res. 2010;10:211–8.PubMedCentralPubMedCrossRef
18.
go back to reference Sun X, Jackson S, Carmichael GA, Sleigh AC. Prescribing behaviour of village doctors under China’s New Cooperative Medical Scheme. Soc Sci Med. 2009;68:1775–9.PubMedCrossRef Sun X, Jackson S, Carmichael GA, Sleigh AC. Prescribing behaviour of village doctors under China’s New Cooperative Medical Scheme. Soc Sci Med. 2009;68:1775–9.PubMedCrossRef
19.
go back to reference Yip W, Hsiao WC. Market watch: the Chinese health system at a crossroads. Health Affairs. 2008;27:460–8.PubMedCrossRef Yip W, Hsiao WC. Market watch: the Chinese health system at a crossroads. Health Affairs. 2008;27:460–8.PubMedCrossRef
20.
go back to reference Yao KH, Yang YH. Streptococcus pneumonia diseases in Chinese children: past, present and future. Vaccine. 2008;26(35):4425–33.PubMedCrossRef Yao KH, Yang YH. Streptococcus pneumonia diseases in Chinese children: past, present and future. Vaccine. 2008;26(35):4425–33.PubMedCrossRef
21.
go back to reference Li J, Ma Y, Wang Z, et al. Klebsiella pneumonia: epidemiology and analysis of risk factors for infections caused by resistant strains. Chin Med J. 2002;115(8):1158–62.PubMed Li J, Ma Y, Wang Z, et al. Klebsiella pneumonia: epidemiology and analysis of risk factors for infections caused by resistant strains. Chin Med J. 2002;115(8):1158–62.PubMed
22.
go back to reference Dong L, Yan H, Wang D. Antibiotic prescribing patterns in village health clinics across 10 provinces of Western China. J Antimicrob Chemother. 2008;62(2):410–5.PubMedCrossRef Dong L, Yan H, Wang D. Antibiotic prescribing patterns in village health clinics across 10 provinces of Western China. J Antimicrob Chemother. 2008;62(2):410–5.PubMedCrossRef
23.
go back to reference Dong L, Yan H, Wang D. Drug prescribing indicators in village health clinics across 10 provinces of Western China. Fam Pract. 2011;28(1):63–7.PubMedCrossRef Dong L, Yan H, Wang D. Drug prescribing indicators in village health clinics across 10 provinces of Western China. Fam Pract. 2011;28(1):63–7.PubMedCrossRef
25.
go back to reference Li Q, Zeng FD. The necessity to develop the national drug policy in our country (in Chinese). Chin J Pharmaco Epidemiol. 2003;12(6):281–5. Li Q, Zeng FD. The necessity to develop the national drug policy in our country (in Chinese). Chin J Pharmaco Epidemiol. 2003;12(6):281–5.
26.
go back to reference International Network for Rational Use of Drugs. How to investigate drug use in health facilities: selected drug use indicators. Geneva: WHO; 1993. International Network for Rational Use of Drugs. How to investigate drug use in health facilities: selected drug use indicators. Geneva: WHO; 1993.
27.
go back to reference Meng Q, Xu L, Zhang YG, et al. Trends in access to health services and financial protection in China between 2003 and 2011: a cross-sectional study. Lancet. 2012;379(9818):805–14.PubMedCrossRef Meng Q, Xu L, Zhang YG, et al. Trends in access to health services and financial protection in China between 2003 and 2011: a cross-sectional study. Lancet. 2012;379(9818):805–14.PubMedCrossRef
28.
go back to reference Babiarz KS, Miller G, Yi H, et al. New evidence on the impact of China’s New Rural Cooperative Medical Scheme and its implications for rural primary healthcare: multivariate difference-in-difference analysis. BMJ. 2010;341:1–9.CrossRef Babiarz KS, Miller G, Yi H, et al. New evidence on the impact of China’s New Rural Cooperative Medical Scheme and its implications for rural primary healthcare: multivariate difference-in-difference analysis. BMJ. 2010;341:1–9.CrossRef
29.
go back to reference Couper MC, Mehta D. WHO model formulary. Geneva: WHO; 2002. Couper MC, Mehta D. WHO model formulary. Geneva: WHO; 2002.
31.
go back to reference Carandang ED. Rational drug use: Philippine experience. In: Chaudhury RR, Somrongthorn, editors. International experience in rational use of drugs. Bangkok: The College of Public Health, Chulalongkorn University; 1999. Carandang ED. Rational drug use: Philippine experience. In: Chaudhury RR, Somrongthorn, editors. International experience in rational use of drugs. Bangkok: The College of Public Health, Chulalongkorn University; 1999.
32.
go back to reference Chetley A, Rohde JE. National drug policies as the first step towards rational drug use: the experience of Bangladesh. In: Chaudhury RR, editors. International experience in rational use of drugs. Bangkok: The College of Public Health, Chulalongkorn University; 1994. Chetley A, Rohde JE. National drug policies as the first step towards rational drug use: the experience of Bangladesh. In: Chaudhury RR, editors. International experience in rational use of drugs. Bangkok: The College of Public Health, Chulalongkorn University; 1994.
33.
go back to reference Chaudhury RR, Parameswar R, Gupta U, et al. Quality medicines for the poor: experience of the Delhi programme on rational use of drugs. Health Policy Plan. 2005;20(2):124–36.PubMedCrossRef Chaudhury RR, Parameswar R, Gupta U, et al. Quality medicines for the poor: experience of the Delhi programme on rational use of drugs. Health Policy Plan. 2005;20(2):124–36.PubMedCrossRef
34.
go back to reference World Health Organization. Promoting rational use of medicines: core components. Geneva: WHO; 2002. World Health Organization. Promoting rational use of medicines: core components. Geneva: WHO; 2002.
35.
go back to reference Bank World. Financing, pricing, and utilization of pharmaceuticals in China: the road to reform. Washington, DC: World Bank; 2010. Bank World. Financing, pricing, and utilization of pharmaceuticals in China: the road to reform. Washington, DC: World Bank; 2010.
36.
go back to reference Figueiras A, Sastre I, Gestal-Otero JJ. Effectiveness of educational interventions on the improvement of drug prescription in primary care: a critical literature review. J Eval Clin Pract. 2001;7(2):223–41.PubMedCrossRef Figueiras A, Sastre I, Gestal-Otero JJ. Effectiveness of educational interventions on the improvement of drug prescription in primary care: a critical literature review. J Eval Clin Pract. 2001;7(2):223–41.PubMedCrossRef
37.
go back to reference Mandal SC, Mandal M. Improving use of medicines in the community through interventions. Value Health. 2011;14(7):A340.CrossRef Mandal SC, Mandal M. Improving use of medicines in the community through interventions. Value Health. 2011;14(7):A340.CrossRef
38.
go back to reference Chakraborty A, Roy S, Loeffler J, Chaves RL. Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother. 2009;64(1):151–8.PubMedCentralPubMedCrossRef Chakraborty A, Roy S, Loeffler J, Chaves RL. Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother. 2009;64(1):151–8.PubMedCentralPubMedCrossRef
Metadata
Title
Does Economic Incentive Matter for Rational Use of Medicine? China’s Experience from the Essential Medicines Program
Authors
Mingsheng Chen
Lijie Wang
Wen Chen
Luying Zhang
Hongli Jiang
Wenhui Mao
Publication date
01-03-2014
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 3/2014
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-013-0068-z

Other articles of this Issue 3/2014

PharmacoEconomics 3/2014 Go to the issue